DenialHelpUnderstand your c. difficile infection denial. Build a reviewable appeal.
Upload the denial notice, verify the extracted facts, identify missing evidence, and prepare a package for treating-clinician review. The notice and applicable rules determine the available route and deadline.
Start my appeal→
See how it worksThe denial notice
Confirm the payer's stated reason, plan language, dates, and review rights from the actual notice.
Facts and evidence
Keep extracted information linked to its source. Unknown facts stay unknown until you or the clinician confirms them.
Route and review
Classify the next step, verify any deadline, and identify what requires treating-clinician review or signature.
Four clear stages.
Upload your denial — and any clinical records you have
Take a photo, scan, or upload PDFs of the denial letter. Adding labs, prior PA letters, or visit notes makes the appeal stronger — but the denial alone is enough to start.
Confirm a few facts
We pre-fill what was extracted. You confirm, correct, or leave it unknown.
We draft your appeal
A source-linked draft and evidence checklist for treating-clinician review.
Your doctor signs and files
We email the letter to you. Your doctor reviews, signs, and submits.
Common questions
Can I appeal a denied insurance claim for C. difficile infection?
The denial notice and governing plan or program determine whether and how the decision can be challenged. DenialHelp first classifies the route, then organizes the relevant facts and sources. Filing dates vary and must be verified against the actual notice.
What does DenialHelp cost for a C. difficile infection appeal?
$39 for a first-level appeal. Other review levels use the current prices shown on the pricing page. The refund promise concerns the described deliverable, not the insurer's decision.
Who reviews and signs the C. difficile infection appeal letter?
The patient's treating physician reviews and signs the appeal letter before it is submitted to the insurer. DenialHelp drafts the letter; the patient and prescribing physician are responsible for submission. We do not file appeals on behalf of patients.
What treatments are covered under C. difficile infection?
Fidaxomicin (Dificid) 200 mg PO BID x 10 days — IDSA/SHEA 2021 PREFERRED first-line for initial AND recurrent CDI; FDA-approved May 2011, Fidaxomicin extended-pulsed (200 mg BID days 1-5, then 200 mg QOD days 7-25) per EXTEND Lancet ID 2018, Vancomycin oral capsules 125 mg PO QID x 10 days — first-line alternative per IDSA/SHEA 2021 (acceptable when fidaxomicin unavailable), Vancomycin enema (rectal 500 mg in 100 mL saline q6h) for fulminant/ileus or severe-complicated CDI, Bezlotoxumab (Zinplava) 10 mg/kg IV x 1 — anti-toxin-B mAb add-on for recurrence PREVENTION; FDA-approved Oct 2016, Rebyota (fecal microbiota, live-jslm) 150 mL rectal x 1 — first FDA-approved fecal microbiota product, Nov 30 2022, for recurrence prevention after standard antibiotic, Vowst (fecal microbiota spores, live-brpk) PO 4 caps daily x 3 days — first ORAL FDA-approved microbiota; Apr 26 2023; recurrence prevention after antibiotics, Traditional FMT (fecal microbiota transplant — colonoscopic / NJ tube / capsule) — investigational / IND research-protocol per FDA enforcement discretion
Ready to fight your denial?
Our free pre-payment review runs before checkout. Refund requests made within 7 calendar days of payment are processed automatically; later requests are reviewed under the Terms. A refund policy is not a promise of a payer outcome.
Start my appeal→